See more : Greenply Industries Limited (GREENPLY.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Paradigm Biopharmaceuticals Limited (PBIGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Paradigm Biopharmaceuticals Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Planet Home Investment AG (ILK1.SG) Income Statement Analysis – Financial Results
- Graphite Bio, Inc. (GRPH) Income Statement Analysis – Financial Results
- G Squared Ascend II Inc. (GSQB-WT) Income Statement Analysis – Financial Results
- National Plywood Industries Limited (NATPLY.BO) Income Statement Analysis – Financial Results
- Live Oak Crestview Climate Acquisition Corp. (LOCC) Income Statement Analysis – Financial Results
Paradigm Biopharmaceuticals Limited (PBIGF)
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.80K | 46.76K | 79.22K | 20.55K | 0.00 | 2.98M | 2.68M | 1.82M | 1.29M | 0.00 | 0.00 |
| Cost of Revenue | 8.99K | 18.83K | 143.75K | 99.14K | 213.12K | 8.35K | 15.35K | 16.63K | 2.54K | 0.00 | 0.00 |
| Gross Profit | 56.81K | 27.93K | -64.53K | -78.59K | -213.12K | 2.98M | 2.67M | 1.81M | 1.29M | 0.00 | 0.00 |
| Gross Profit Ratio | 86.34% | 59.74% | -81.45% | -382.42% | 0.00% | 99.72% | 99.43% | 99.09% | 99.80% | 0.00% | 0.00% |
| Research & Development | 58.33M | 52.68M | 39.01M | 33.52M | 12.79M | 7.90M | 6.59M | 4.23M | 2.87M | 157.71K | 0.00 |
| General & Administrative | 6.22M | 6.56M | 7.93M | 8.75M | 4.17M | 4.05M | 2.33M | 1.89M | 1.45M | 219.90K | 231.44K |
| Selling & Marketing | 0.00 | 822.70K | 918.86K | 836.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 0.00 |
| SG&A | 6.22M | 6.56M | 7.93M | 8.75M | 4.17M | 4.05M | 2.33M | 1.89M | 1.45M | 1.41M | 231.44K |
| Other Expenses | 0.00 | 6.74M | 8.66M | 8.71M | 3.70M | 2.98M | 2.68M | 1.82M | 1.29M | 0.00 | 0.00 |
| Operating Expenses | 56.81K | 60.07M | 47.93M | 43.31M | 17.17M | 11.95M | 8.94M | 6.14M | 4.32M | 1.57M | 231.44K |
| Cost & Expenses | 65.11M | 60.09M | 48.07M | 43.41M | 17.17M | 11.95M | 8.94M | 6.14M | 4.32M | 1.57M | 231.44K |
| Interest Income | 407.01K | 1.40M | 51.74K | 209.13K | 997.65K | 261.71K | 53.90K | 25.62K | 103.57K | 0.00 | 0.00 |
| Interest Expense | 14.37K | 16.42K | 28.63K | 37.72K | 34.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 146.74K | 153.66K | 193.25K | 210.06K | 213.12K | 8.35K | 15.35K | 16.63K | 2.54K | 1.57M | 231.44K |
| EBITDA | -58.49M | -51.89M | -39.16M | -34.05M | -16.88M | -5.02M | -8.93M | -4.28M | -4.32M | 0.00 | 0.00 |
| EBITDA Ratio | -88,893.74% | -110,978.61% | -49,429.44% | -165,690.53% | 0.00% | -168.07% | -332.77% | -335.89% | -334.62% | 0.00% | 0.00% |
| Operating Income | -65.11M | -51.89M | -39.22M | -34.26M | -12.26M | -5.02M | -8.94M | -6.14M | -4.32M | -1.57M | -231.44K |
| Operating Income Ratio | -98,954.68% | -110,978.61% | -49,506.40% | -166,712.71% | 0.00% | -168.35% | -333.35% | -336.81% | -334.82% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.46M | -16.42K | -28.63K | -37.72K | 4.66M | -6.88M | -4.47K | 25.62K | 77.71K | 7.33K | 0.00 |
| Income Before Tax | -58.65M | -51.91M | -39.25M | -34.30M | -12.30M | -15.63M | -6.19M | -4.28M | -2.92M | -1.57M | -231.44K |
| Income Before Tax Ratio | -89,138.58% | -111,013.71% | -49,542.54% | -166,896.27% | 0.00% | -523.73% | -230.76% | -234.49% | -226.60% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.04M | 8.69M | 8.75M | 3.73M | 6.66M | -69.25K | -42.25K | -106.10K | 7.33K | 0.00 |
| Net Income | -58.65M | -51.91M | -39.25M | -34.30M | -12.30M | -15.63M | -6.19M | -4.28M | -2.92M | -1.57M | -231.44K |
| Net Income Ratio | -89,138.58% | -111,013.71% | -49,542.54% | -166,896.27% | 0.00% | -523.73% | -230.76% | -234.49% | -226.60% | 0.00% | 0.00% |
| EPS | -0.20 | -0.18 | -0.16 | -0.16 | -0.06 | -0.11 | -0.05 | -0.04 | -0.03 | -0.05 | 0.00 |
| EPS Diluted | -0.20 | -0.18 | -0.16 | -0.16 | -0.06 | -0.11 | -0.05 | -0.04 | -0.03 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 293.28M | 289.68M | 240.96M | 212.19M | 208.27M | 148.13M | 117.02M | 98.58M | 83.79M | 33.15M | 0.00 |
| Weighted Avg Shares Out (Dil) | 293.28M | 289.68M | 241.82M | 212.19M | 208.27M | 148.13M | 117.02M | 98.58M | 83.79M | 33.15M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports